xml version="1.0" encoding="utf-8"?               

   0000001800 false Common Shares, Without Par Value ABT        0000001800   2020-02-06 2020-02-07     0000001800  us-gaap:CommonStockMember exch:XCHI    2020-02-06 2020-02-07     0000001800  us-gaap:CommonStockMember exch:XNYS    2020-02-06 2020-02-07    iso4217:USD   xbrli:shares     iso4217:USD   xbrli:shares       

 Common Shares, Without Par Value   ABT      

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D. C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the 

Securities Exchange Act of 1934 

February 7, 2020 

Date of Report (Date of earliest event reported) 

ABBOTT LABORATORIES 

(Exact name of registrant as specified in charter) 

  [DATA_TABLE_REMOVED] 

100 Abbott Park Road 

Abbott Park, Illinois 60064-6400 

(Address of principal executive offices)(Zip Code) 

Registrant’s telephone number, including area code: (224) 667-6100 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities Registered Pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ¨ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

On February 7, 2020, Philip P. Boudreau, 47, was appointed Vice President, Finance and Controller, effective March 1, 2020. Mr. Boudreau has served as Abbott’s Divisional Vice President, Controller, Medical Devices since 2017 and served as Divisional Vice President, Controller and Commercial Support, Point of Care from 2012 to 2017. He joined Abbott in 1997. 

Mr. Boudreau will receive compensation pursuant to certain plans provided by Abbott, including a base salary, annual incentive, long-term incentive, and other benefits typically available to other similarly situated executive officers. 

SIGNATURE 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED]